30 results about "TMPRSS2" patented technology

The present invention generally relates to substances and methods useful for the treatment of neoplastic disease. More specifically, it relates to cancer selective promoters and their use in oncolytic adenoviral vectors. The oncolytic adenoviral vectors are useful in methods of gene therapy. The promoters and the oncolytic adenoviral vectors are useful in methods for screening for compounds that modulate the expression of the cancer selective genes.

Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.

The present invention is directed to specific chromosomal rearrangements that are associated with prostate tumors that respond to compounds acting at estrogen receptors. Patients having the TMPRSS2-ERG fusion, may be treated with agonists of the estrogen beta receptor or antagonists of the estrogen alpha receptor.

The present invention provides methods for treating or preventing influenza virus infection. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising a type II transmembrane serine protease (TTSP) inhibitor. The TTSP inhibitor preferably functions by inhibiting the proteolytic cleavage of influenza hemagglutinin (HA0) into the functional subunits HA1 and HA2. In certain embodiments, the TTSP inhibitor is an inhibitor of transmembrane protease serine S1 member 2 (TMPRSS2), such as an anti-TMPRSS2 antibody or antigen-binding fragment thereof.

The invention relates to a detection method of prostatic cancer related fusion gene Fish. The detection method comprises the steps of: carrying out conventional pretreatment on prostatic cancer tissue paraffin sections, then carrying out in-situ hybridization with a two-color fusion probe, and judging whether the prostatic cancer related fusion gene exists according to the detected fluorescence signal. Preferably, the two-color fusion probe is TMPRSS2 / ERG two-color fusion probe, TMPRSS2 / ETV1 two-color fusion probe or TMPRSS2 / ETV4 two-color fusion probe, wherein the TMPRSS2, ERG, ETV1 and ETV4 are respectively nucleotide sequences shown in SEQ ID NO: 1-4. The invention also relates to a correlated two-color fusion probe and a kit. The detection method of the prostatic cancer related fusion gene Fish is ingenious in design, is simple to operate, greatly increases specificity and sensitivity, can be used for quickly, accurately and visually detecting the prostatic cancer related fusion gene, and has accurate and reliable detection result, thus the detection method can be used as a reference for diagnosing prostatic cancer by physicians, and is suitable for large-scale popularization and application.

The invention relates to the technical field of gene detection and provided a method for extracting total RNA from urine of a subject and detecting TMPRSS2-ERG mRNA and PSA mRNA as well as primers which specifically amplify the TMPRSS2-ERG mRNA and PSA mRNA, wherein the primers comprise two groups of PCR amplification nucleic acid primers for detecting the TMPRSS2-ERG mRNA and PSA mRNA. The lengths of the primers are 17-24bp, and the primers specifically amplify a TMPRSS2-ERG mRNA fragment and a PAS mRNA fragment. The ratio of the TMPRSS2-ERG mRNA / PAS mRNA is measured and a TMPRSS2-ERG score is calculated by virtue of an amplification result, so that the purpose of early diagnosis of prostatic cancer and estimation of prognosis is realized.

The invention discloses a gene chip for predicting RNA virus infected severe case. The gene chip comprises probes for capturing the following genes of ACE, ANGPT2, ASRD, CD55, FAAH, GLDC, IFITM3, IL1A, IL1B, IL1RN, IL6, IL10, IL17, IL28B, IRAK3, LGALS1, LRRC16A, MBL-2, NAMPT, NFE2L2, PI3, POPDC3, PPFIA1, SP-A2, SP-B, ST3GAL1, TLR1, TLR3, TMPRSS2, TNFA, VEGF, XKR3, ACYP2, BCL2L1, CTC1, CXCR4, NFY1,OBFC1, PXR, RTEL1, TERC, TERT, ZNF208, ZNF311, and ZNF676.

Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG anti-body. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2 / ERG, SLC45A3 / ERG, or NDRG1 / ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting. The antibodies can also be used to inhibit the activity of ERG or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2 / ERG, SLC45A3 / ERG, or NDRG1 / ERG fusion transcript and to treat malignancies associated with overexpression of ERG or an ERG fusion event, such as prostate cancer, Ewing's sarcoma, acute myeloid leukemia, acute T-lymphoblastic leukemia, endothelial cancer, and colon cancer.

Described herein are methods, compositions and kits directed to the detection the 5′ portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).

The invention belongs to the field of airway inflammation medicine application, and relates to application of melatonin in preparation of a medicine for inhibiting expression of a novel coronavirus SARS-CoV-2 receptor. In the application, the melatonin can effectively alleviate OVA-induced allergic airway inflammation, and can significantly inhibit expression increase of a plurality of SARS-CoV-2 related key receptors, including ACE2, exfoliated sACE2, TMPRSS2, Calmodulin and ADAM17, in mouse and human primary bronchial epithelial cells caused by respiratory allergen exposure, so that the melatonin can be used for inhibiting the expression increase of a plurality of SARS-CoV-2 related key receptors, such as ACE2, exfoliated sACE2, TMPRSS2, Calmodulin and ADAM17. It is indicated that airway inflammatory diseases such as asthma may be a risk factor of SARS-CoV-2 infection, and the melatonin significantly inhibits expression of an SARS-CoV-2 receptor, especially ACE2 and shedding of an extracellular domain, so that a basis is provided for application of the melatonin in preparation of drugs for treating novel coronavirus pneumonia (COVID-19).

The invention relates to application of an exosome gene, a prostate cancer detector, and a detection kit and a detection device of the prostate cancer detector. The application of the exosome gene as a biomarker in preparation of a prostate cancer detection reagent, a prostate cancer detection kit or a prostate cancer detection device is characterized in that the exosome gene contains at least one of a PCA3 gene, an SPDEF gene and a TMPRSS2: ERG fusion gene. The biomarker is used for preparing a prostate cancer detection reagent, a prostate cancer detection kit or a prostate cancer detection device, and the positive detection rate of prostate cancer is high.

The invention belongs to the technical field of medicines, and particularly relates to application of a thioimidazolidone medicine or pharmaceutically acceptable salt thereof to preparation of a medicine for treating ACE2 and TMPRSS2 protein disorder related diseases, in particular to application to preparation of a medicine for treating COVID-19 diseases.

Described herein are methods, compositions and kits directed to the detection the 5′ portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.

The present invention relates to a method of assessing the viability of an embryo, wherein the method comprises a step of: measuring the level and / or activity of a protein marker selected from either TMPRSS2 or PRSS8 in a sample of culture medium, wherein the sample has been obtained from the in vitro culture medium of an embryo produced by in vitro fertilization, wherein the level and / or activity of the protein marker is indicative of the viability of the embryo.

The invention discloses application of harringtonine to preparation of a novel coronavirus resisting medicine, and belongs to the technical field of antiviral medicine preparation, the medicine is analyzed through an SARS-CoV-2-Sh / CMC model and a TMPRSS2h / CMC model, and the binding specificity of the harringtonine and SARS-CoV-2 S protein and cell TMPRSS2 enzyme is determined; the SARS-CoV-2 pseudovirus is utilized to infect ACE2 high-expression cells and ACE2 / TMPRSS2 common high-expression cells, and it is proved that the drug has the characteristic of double targets; a Vero E6 cell is infected by using an SARS-CoV-2 original strain and a Delta 630 mutant strain, and it is proved that the medicine has a remarkable SARS-CoV-2 resisting effect and is more sensitive to the inhibiting effect of the Delta 630 mutant strain.

The invention discloses a polygene detection kit for cancer prognosis. The kit comprises a detection reagent capable of detecting the expression levels of MCM2, GATM, PTGDS, ETV1, CASP3, NOTCH3, WNT5A, GLIS1, TNFRSF10B, COL4A6, MMP19, MSR1, PALLD, CCNG2 and TMPRSS2. The present invention provides a kit capable of efficiently predicting prognosis of cancer.

The invention relates to a multiplex fluorescence PCR kit for detecting prostate cancer. The multiplex fluorescence PCR kit comprises a primer group and fluorescence probes, wherein the primer group is used for amplifying three fusion genes TMPRSS2-ERG, TMPRSS2-ETV1 and TMPRSS2-ETV4, and the fluorescence probes correspond to the three fusion genes respectively; the primer group comprises five primers with the nucleotide sequences as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 respectively; and a probe group comprises three fluorescent probes with the nucleotidesequences as shown as SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8 respectively. The kit used for detecting the prostate cancer is simple, efficient, relatively high in accuracy, sensitivity and specificity and low in cost.

The embodiment of the invention provides TMPRSS2 mutant protein, an expression carrier and an expression engineering bacterium thereof, and a preparation method of the expression carrier of the TMPRSS2 mutant protein, and the preparation method of the expression engineering bacterium of the TMPRSS2 mutant protein. The amino acid sequence of the above TMPRSS2 mutant protein is disclosed by SEQ ID NO.7; the nucleotide sequence of the expression zone of the expression carrier comprises a nucleotide sequence disclosed by SEQ ID NO.3; and the engineering bacterium comprises the expression carrier of the TMPRSS2 mutant protein. Wild TMPRSS2 protein can carry out self cutting between Arg255 and Ile256 so as to carry out active form conversion, the wild TMPRSS2 protein has self shearing, and protein purity is low. By use of the embodiment of the invention, through point mutation, the TMPRSS2 protein mutant capable of carrying out lactation cell expression is realized, expression and purification are successfully carried out, and the TMPRSS2 high-purity and high-activity protein is obtained.

The invention discloses a kit for detecting prostate cancer and a preparation method of the kit. Through the combination of an optimization TMA technology and a nested PCR technology and by adopting the combined detection of four biomarkers of PCA3, PSMA, TMPRSS2-ERG and PSA, the sensitivity and specificity of early diagnosis of prostate cancer are improved, and the detection kit with low cost andrapid detection of multiple markers is developed. The gaps in domestic medical diagnostic technology is made up, the diagnosis rate of early prostate cancer is improved, and the pain of prostate cancer biopsy is reduced.

The invention relates to a method of post-surgical risk stratification of a prostate cancer subject, comprising determining a transmembrane protease, serine 2-ETS-related gene (TMPRSS2-ERG) fusion status in a biological sample obtained from the subject, determining a gene expression profile for each of one or more phosphodiesterase 4D variants in a biological sample obtained from the subject, determining an expression based risk score for the subject based on the gene expression profile for a selected phosphodiesterase 4D variant, and determining a post-surgical prognostic risk score for the subject based on the expression based risk score and post-surgical clinical variables of the subject, wherein the selected phosphodiesterase 4D variant is selected depending on the TM-PRSS2-ERG fusion status. This may allow for an improved stratification of the subject in a post-surgical setting that may result in better post-surgical, secondary treatment decisions.

This invention provides a bispecific antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically binds to the extracellular portion of human TMPRSS2 (hTMPRSS2); (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and / or a synthetic MCA-based peptide; and (iv) specifically inhibits the entry into hACE2+ / hTMPRSS2+ human cells of a pseudovirus bearing SARS-CoV-2 S protein. This invention also provides related pharmaceutical compositions, recombinant nucleic acid molecules, vectors, AAV particles, therapeutic and prophylactic methods, and kits.

The present invention relates to methods for treating or preventing a coronavirus infection with serine protease inhibitors targeted against the host protease, transmembrane serine protease 2 (TMPRSS2), and related compositions and methods.

The invention provides a primer probe combination for early diagnosis, metastasis early warning and prognosis evaluation of prostate cancer, a kit and application of the primer probe combination and the kit. The primer probe combination comprises a first group of primer pairs, a second group of primer pairs and a third group of primer pairs, wherein the first group of primer pairs is used for detecting the PCA3 gene and has nucleotide sequences as shown in SEQ ID NO: 1-2; the second group of primer pairs is used for detecting the PSA gene and has nucleotide sequences as shown in SEQ ID NO: 4-5; the third group of primer pairs is used for detecting the TMPRSS2-ERG fusion gene and has nucleotide sequences as shown in SEQ ID NO: 7-8; the probes correspond to the three groups of primer pairs. The method not only realizes early diagnosis of the prostate cancer, but also realizes effective evaluation of metastasis and deterioration risks of the prostate cancer of a diagnosed patient, and is suitable for large-scale population screening and general survey.

The invention discloses a nanogold-labeled chip for polygene diagnosis of prostate cancer. The nanogold-labeled chip mainly comprises 11 genes, a prostate cancer cell strain RNA (Ribonucleic Acid), a nanogold-labeled oligonucleotide probe and nitrocellulose, wherein the 11 genes are obtained by selection of the gene chip and verification of fluorescent quantitation polymerase chain reaction (PCR), have obvious expression difference in prostate cancer and benign prostatic hyperplasia and include IGF1, P27, AR, PSMA, KLK3, PCNA, Ki-67, KLK1, KLK2, TMPRSS2 and SREBF2. The nanogold-labeled chip for polygene diagnosis of prostate cancer can be applied in clinically early diagnosis on prostate cancer.